Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Consensus average price target is $101.23, but have fun while you can. https://www.benzinga.com/quote/NVCR/analyst-ratings
lol. Learningcure2020, a LIFTIME, paid NWBO Basher Does Not Realized that their Constant Years of Attempt to Diminish NWBO Technology has massively Backfired....
Yes, Many NWBO Investors Got Tired, are here & Everywhere giving shameless BS posters like you, a test of your own Dumb Trashy Approach against NWBO...
You all, Particularly you, don't need anyone to try to embarrass you, you have done and doing a great job showing who you are = a waist of a being!!
hey jondoeuk how much are you down on this collapse? :)
Read carefully the selling records of the NVCR management. They are smart enough to realize there is no chance Optune can compete against DCVax-L once it hits the market.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172471927
It is about spreading the truth.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172471927
They are nothing more than bagholders and paid pumpers, some of which are utter filth https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172473739
NWBO has been using third parties for donkey's years https://www.nasdaq.com/articles/behind-promotion-northwest-bio-2014-07-07
First time here. Wow! just look at all the NWBO soldiers camping out here. Back on their homeland they try to embarrass and threaten anyone who criticizes dcvax. But just look at the cult get all over Novo!!!
Yes it was! I own it! But I will hold for better days! God bless and take care!
Awesome sauce
The selling records of the NVCR managment. Pay special attention to the amount of money they made after May 28, 2018 on which the first results from p3 trial of DCVax-L were published. It seems to me every management crew of NVCR is ready to abandon the ship.
Michael J. Ambrogi has been appointed as Vice President - Senior Technology Fellow of the Company effective 9/1/2020. He has been our Chief Operating Officer since 2010 and previously served as our U.S. General Manager from 2006 to 2010. Mr. Ambrogi has overall responsibility for our ongoing operations, engineering, manufacturing, service and human resources activities worldwide.
Asaf Danziger has served as Chief Executive Officer of Novocure since 2002 and has been a director of Novocure since 2012. Mr. Danziger has led the company and the development of TTFields therapy from preclinical testing through regulatory approvals to commercial sales in Europe and the United States.
Charles G. Phillips III has been a director of Novocure since 2012 and has served on our audit committee and as the chairperson of our compensation committee since 2012.
Mr. Doyle has served as our Executive Chairman since 2016, as Chairman of the Board since 2009 and as a member of our Board of Directors since 2004.
Dr. Eilon Kirson joined Novocure in 2002 and served as Chief Medical Officer until 2012 when he was promoted to Chief Science Officer and Head of Research and Development.
Dr. Ely Benaim joined Novocure in April 2019 and serves as Chief Medical Officer.
Frank Leonard has served as Novocure’s Chief Development Officer since September 2020. This newly created executive role has responsibility for engineering, product development, business development, and the overall strategic and operational leadership of Novocure’s innovation platforms.
Gabriel Leung has been Vice Chairman and a director of Novocure since 2011.
Todd Longsworth joined Novocure in 2012 and serves as General Counsel.
Wilco Groenhuysen has served as Novocure’s Chief Operating Officer since September 2020. He is responsible for the general and administrative management of the company, the strategic and operational leadership of Novocure’s supply chain, warehousing and distribution, quality assurance and information technology operations. Mr. Groenhuysen is tasked to ensure organizational readiness in anticipation of the completion of four phase 3 clinical trials over the next few years.
https://investorshub.advfn.com/uimage/uploads/2023/7/30/iqylhAsaf_Danziger_NVCR.png
I know you definitely wouldn't listen to an anonymous poster. Since your proceeds will all go to the charity which helps people in need, I respect your kind deeds, if I were you, I would invest heavily in NWBO and you most likely recover all your loss in NVCR and have huge return in short term.
NVCR Out of the Gate on Massive HYPE, Heading to Pennyland on trial findings that the tech is Not Good Enough to waste time on IMO
Hahaha, hilarious prediction
Hahaha . What amusing predictions in hindsight.
You know for a fact that all NVCR active GBM patients will switch to NWBO overnight once DCVax-L has the approval which will happen soon. That means the main source of income will be gone.
https://seekingalpha.com/article/4620446-novocure-limited-nvcr-q2-2023-earnings-call-transcript
The LUNAR results have been accepted to a high impact journal and are now awaiting publication. The regulatory team recently completed the submission for CE Mark. The next step is for them to finalise an FDA PMA submission later this year. If it is approved, will add something to revenue, but I don't see it as a game changer, even in this large market.
jondoe how much are you down on this? :)
In 2016, NCI sponsored a massive clinical trial on rare cancers. Take a look at the list of all rare cancers. The missing one was GBM. Was it because Optune was a huge success back then? I guess not. It was because the combo trial of DCVax-L and poly-iclc was completed in January 2015. NCI found that there was no need to include GBM in the list.
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
https://classic.clinicaltrials.gov/ct2/show/NCT02834013?cond=rare+cancer&lead=National+cancer+institute&draw=2&rank=10
https://classic.clinicaltrials.gov/ct2/show/NCT01204684?cond=glioblastoma&spons=Jonsson&draw=2&rank=15
Here is the dissertation by Joseph Anotnios who was the only Ph.D. student under the direct guidance of Dr. Linda Liau.
https://escholarship.org/content/qt0t37x26s/qt0t37x26s.pdf
Take a look at the results from mouse model. The green line corresponds to the currently undergoing combo trial at UCLA.
https://classic.clinicaltrials.gov/ct2/show/NCT04201873?cond=atl-dc&draw=2&rank=1
People always say that medicine success on animal models would not translate to the one on humans. Here is the amazing part. In the case of DCVax-L, the success on animal models translates.
DCVax-L alone was successful on animal models. Then success was achieved in p1 and p3 trial.
DCVax-L + Poly-ICLC was successful on mouse models. in the human trial, five out of nine patients live over 10 years after three doses of the vaccine within 28 days. No SOC was involved.
https://classic.clinicaltrials.gov/ct2/show/NCT01204684?cond=glioblastoma&spons=Jonsson&draw=2&rank=15
DCVax-L + Poly-ICLC + Keytruda was successful on mouse models too. Likewise we see the incredible data on rGBM patients.
https://classic.clinicaltrials.gov/ct2/show/NCT04201873?cond=atl-dc&draw=2&rank=1
This trial needs elaboration. As a matter of fact, the preliminary results from this trial were so successful that after March 2021 which was the last time the PI, Timothy Cloughesy reported to Merck, all the puzzles started moving. Kevin Duffy joined Regeneron. Oncovir who owns the patent of poly-iclc hired several high-caliber professionals. It should be noted that National Cancer Institute is also the sponsor of the trial. No doubt Timothy would report to NCI too. People who really have interest may check who was later promoted to be the director of NCI and later the director of NIH.
jondoeuk,
FYI, I don't short stocks, not to mention a stock related to cancer treatment. The problem with NVCR is that the management misled investors in the meantime they sold a big chunk of their position. That's why they are facing lawsuit.
dstock07734
Re: None
Thursday, July 27, 2023 12:54:46 PM
Post#
358
of 360
Here is the presentation from Dr. Bosch on June 3 at ASCO.
Simply take a look how many tumor associated peptides that the MHC Class 2 molecules on the surface of dendritic cells can present to the immune system. Go through these cancer vaccine companies using neo-antigen technology or mRNA technology. Will these companies be able to present huge number of peptides so that t-cells can have fully comprehensive data to identify which cell is cancer cell and which cell is normal cell? None of them can.
These cancer vaccine companies at most can only present less than 50 tumor-specific peptides to the immune system. More importantly, at best they can only activate CD8 t cells which will not trigger immune memory.
You were a big advocate when I said months ago with unequivocal evidence that something smelt real fishy about NVCR and the management were all about to abandon the ship.
Are you still holding your hope up? There is no future for the company. The tailspin mode will continue.
Here is the presentation from Dr. Bosch on June 3 at ASCO.
Simply take a look how many tumor associated peptides that the MHC Class 2 molecules on the surface of dendritic cells can present to the immune system. Go through these cancer vaccine companies using neo-antigen technology or mRNA technology. Will these companies be able to present huge number of peptides so that t-cells can have fully comprehensive data to identify which cell is cancer cell and which cell is normal cell? None of them can.
These cancer vaccine companies at most can only present less than 50 tumor-specific peptides to the immune system. More importantly, at best they can only activate CD8 t cells which will not trigger immune memory.
Are you laughing at the account name he created?
He needs to change the account name definitely.
Read the story about Owain who had 50% of GBM tumor removed and who tumor tissue was only enough to make three doses of the DCVax-L vaccine. But as his doctor, the world renowned neurosurgeon, said, three doses are enough to reprogram the whole immune system. Owain scanned results showed that the rest of 50% of the tumor shrunk into a small cyst and it keeps shrinking four months after the last shot.
https://www.justgiving.com/crowdfunding/owainjames
You want to know why? The reason is that DCVax-L can activate CD4 t cells which play a critical role in the formation and maintenance of immune memory. The MHC Class 2 molecules can only be found in antigen presenting cells which are only few types in human, such as dendritic cells, B-cells, macrophages. Only these molecules can activate CD4 t cells. Read what Dr. Bosch said in the present in June.
Doubled up on $NVCR today! GLTA
herbied47,
Seekingalpha is not a great source for DDs.
By all means, take a look at the latest presentation of Dr. Bosch. Immunotherapy is the way to treat cancer.
https://nwbio.com/wp-content/uploads/NWBT_ASCO_slides_06032023_FINAL.pdf
Five out of nine patients in the following trial live over ten years after receiving three doses of the vaccine within 28 days. You can see how many times the number of t-cells increases four and eight months after the vaccine.
https://classic.clinicaltrials.gov/ct2/show/NCT01204684?cond=glioblastoma&spons=Jonsson&draw=2&rank=15
Is the glass half full here? Or totally empty? A few objective data points to ponder:
• $1B in cash. To borrow from Jay-Z, NVCR may have 99 problems, but cash ain’t one.
• $500M/ yr GBM business that sustains itself, generating more cash that it consumes
• Every human clinical trial NVCR has ever run has succeeded at hitting its primary endpoint with statistical significance
• 3 ph3 trials will report results over the next ~15 mos: Ovarian, Metis, Pancreatic. All 3 of these trials have straightforward, simple design in cancers with little competitive therapies. If even one of these trials succeeds, it should become a multi-billion dollar blockbuster business line
• In the biotech world, delivering successful clinical trials is hard. Even if NVCR management is weak, if NVCR delivers successful trial wins, somebody will see the value and NVCR might become an acquisition target.
NVCR retailers should be very careful. The CEO has emptied 94% of his position and made over $240m among which $160m was made after the publication of the first paper on the blinded results of p3 DCVax-L clinical trial on May 29 2018. Take a specific look at what he did after the JAMA paper was published on November 17, 2022. Did he sense something? Does it look like he still holds confidence in the company?
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
Absolutely. Right now sp is completely supported by optune. Once DCVax-L has approval, NVCR will be in tail-spin mode. This pattern of CEO selling his shares since the publication of the first paper on the p3 trial of DCVax-L in May 2018 happens to every member of the C-suite of NVCR. It couldn't be more obvious.
I don't think you got the facts correct.
Clearly TTF + SOC delivered the results even worse than SOC. Likewise for the case of TTF + ICI and TTF + DTX except the case PD-L1 expression less than 1%.
The trial was a total failure!
https://www.novocure.com/lunar-phase-3-clinical-trial-demonstrates-statistically-significant-and-clinically-meaningful-extension-in-overall-survival-for-patients-with-metastatic-non-small-cell-lung-cancer-after-platinum-based/
And its going down in front of all eyes!!!
And will continue the down-Is-Goes continiously IMO
Consider please...
-- The LUNAR trial is the first study in more than seven years to show a significant improvement in overall survival in metastatic non-small cell lung cancer post-platinum chemotherapy.
-- How is NSCLC treated in China? In China, platinum-based chemotherapy is standard of care for treating stage IV NSCLC patients, unlike the USA, where checkpoint inhibitors are the dominant choice in first-line.
-- Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China
United States
Lung cancer incidence (overall): 35.1 per 100,000
Lung cancer mortality rate: 27.8 per 100,000
Smoking prevalence (male): 14.4%
Smoking prevalence (female): 11.7%
Outdoor air pollution: 7.4 µg/m3
Indoor air pollution: 0.2% of the population
China
Lung cancer incidence (overall): 35.1 per 100,000
Lung cancer mortality rate: 36.2 per 100,000
Smoking prevalence (male): 44.8%
Smoking prevalence (female): 2%
Outdoor air pollution: 53 µg/m3
Indoor air pollution: 32% of the population
** The stock price reaction to LUNAR is based ENTIRELY on comments made by US physicians and US ICI standard of care.
What did Les say in the Big Biz Show?
This happens to a MB when the Hyped Technology keeps underperforming IMO..
Way lower it goes IMO
I recall he was bragging that he emptied his position on NVCR above $200.
Posting BS against NWBO is no use. The reason is simple. He is against science and science always prevails.
This abstract was published five years ago on DCVax-L + Poly-ICLC. Five out of nine patients are still alive over ten years after three doses of the combination. This is extraordinary considering the fact that maturated dendritic cells can only live one week after reaching lymph nodes. After one month, all the original dendritic cells loaded with tumor antigens were gone. But because of the involvement of MHC Class 2, the anti-tumor immune response keeps going and there is why there is no recurrence.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216157/
LOL - If any wearable wave devices would have any meaningful effect on health, mom & pop shops would have been offering them long ago imo,,
Just not worth the time as so far data has been as good as placebo effect imo..
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
559
|
Created
|
10/07/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |